Researchers evaluated liver test abnormalities in patients hospitalized with COVID-19 and assessed cytokine levels in individuals with vs without abnormal test results.
Researchers sought to determine the prevalence of cardiovascular disease, cirrhosis, metabolic diseases, and chronic kidney disease in lean vs overweight or obese NAFLD.
A team of researchers analyzed the safety, efficacy, and tolerability of seladelpar in patients with compensated liver cirrhosis resulting from primary biliary cholangitis.
